These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36370634)

  • 41. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder.
    Wingerchuk DM; Weinshenker BG; McCormick D; Barron S; Simone L; Jarzylo L
    J Manag Care Spec Pharm; 2022 Dec; 28(12-a Suppl):S3-S27. PubMed ID: 36427336
    [No Abstract]   [Full Text] [Related]  

  • 44. A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report.
    Chen X; Shi Z; Wang R; Zhou H
    Ther Adv Neurol Disord; 2024; 17():17562864241258787. PubMed ID: 39072007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
    Valencia-Sanchez C; Wingerchuk DM
    BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.
    Graf J; Mares J; Barnett M; Aktas O; Albrecht P; Zamvil SS; Hartung HP
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33411674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
    Takai Y; Kuroda H; Misu T; Akaishi T; Nakashima I; Takahashi T; Nishiyama S; Fujihara K; Aoki M
    Mult Scler Relat Disord; 2021 Apr; 49():102750. PubMed ID: 33524925
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case report: Identification of Hepatitis B Virus in the cerebrospinal fluid of neuromyelitis optica spectrum disorders and successful treatment with ofatumumab and inebilizumab.
    Cai L; Liu X; Zhou H; Li J; Zhou D; Hong Z
    Front Immunol; 2024; 15():1351782. PubMed ID: 38426084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
    Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.
    Li X; Xu H; Zheng Z; Ouyang H; Chen G; Lou Z; Chen H; Zhang J; Zhan Y; Mao H; Zhang C; Zhao M; Zhao Y
    BMC Neurol; 2022 Aug; 22(1):304. PubMed ID: 35986246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial.
    Xu Y; Ren Y; Li X; Xu W; Wang X; Duan Y; Liu Y; Zhang X; Tian DC
    Neurotherapeutics; 2021 Apr; 18(2):868-877. PubMed ID: 33469828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Two Cases of Pediatric AQP4-Antibody Positive Neuromyelitis Optica Spectrum Disorder Successfully Treated with Tocilizumab.
    Breu M; Glatter S; Höftberger R; Freilinger M; Kircher K; Kasprian G; Seidl R; Kornek B
    Neuropediatrics; 2019 Jun; 50(3):193-196. PubMed ID: 30913570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
    Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
    Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
    Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
    Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.